Dr. Dagmar García Rivero, director of research at the Finlay Vaccine Institute, affirmed that in order to achieve high immunization coverage to face the pandemic, “it is essential to vaccinate pediatric populations,” although she recalled that “advancing to clinical trials in children requires higher regulatory rigor.”
Cuban researchers hope to begin clinical trials in April of a coronavirus vaccine candidate specifically designed for children between 5 and 18 years of age.
Dr. Dagmar García Rivero, director of research at the Finlay Vaccine Institute (IFV), affirmed this Thursday at a press conference that in order to achieve high immunization coverage to face the pandemic, “it is essential to vaccinate pediatric populations,” although she recalled that “advancing to clinical trials in children requires higher regulatory rigor.”
None of the COVID-19 vaccines already approved in other countries is currently designed for use in children, although there are multinational pharmaceutical companies that are already working on this type of research.
The IFV is the body responsible for the most advanced vaccine candidate in Cuba, Soberana 02, which has just received authorization to begin the third and final phase of clinical trials, in which its effectiveness will be tested on a large scale. If this stage is successful, the Cuban formula could become the first COVID-19 vaccine created in Latin America.
Third phase of trials of Soberana 02 vaccine to start in March in Havana
Studies of a children’s vaccine against coronavirus will be based on evaluating the best formulation of Soberana 02 and also Soberana 01, another of the formulas being developed by the IFV, for pediatric application.
Comments are closed.